Within a very short period of time, there has been a tremendous advance in development of cellular immunotherapies in multiple myeloma (MM). As we have observed during our event last year, a number of groups have presented their data on CAR T-cell therapy in MM. Although the studies are currently small in size, they are accruing patients very quickly, both in the United States and globally.

These developments have highlighted the need for a focused discussion about the state-of-the-art in immune and cellular therapies. With this in mind, the International Myeloma Society (IMS) is organizing the 2nd Immune Effector Cell Therapy in Multiple Myeloma Workshop. This two-day meeting will review CAR-T clinical data and promising preclinical leads, gain consensus on issues in management of toxicity, and discuss ongoing and future clinical trials. This year we are also including a session on T cell-engaging bispecific antibody-based approaches.
# PRELIMINARY PROGRAM

## Friday, May 7, 2021

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:00-8:15 am</td>
<td><strong>Introduction and Welcome Remarks</strong>&lt;br&gt;Adam Cohen, MD; Hermann Einsele, MD, FRCP; and Nikhil Munshi, MD</td>
<td></td>
</tr>
<tr>
<td>8:15-8:30 am</td>
<td><strong>How will CAR T and bispecifics fit in MM treatment paradigm?</strong>&lt;br&gt;Kenneth Anderson, MD</td>
<td></td>
</tr>
</tbody>
</table>

### SESSION 1: UPDATE ON BCMA CAR T CLINICAL DATA  
(Session Chairs: Nikhil Munshi, MD and Paula Rodriguez-Otero, MD)

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:30-8:45 am</td>
<td><strong>Legend LCAR-B38M update</strong>&lt;br&gt;Sundar Jagannath, MD</td>
<td></td>
</tr>
<tr>
<td>8:45-9:00 am</td>
<td><strong>CARTITUDE-1 phase 1 update</strong>&lt;br&gt;Deepu Madduri, MD</td>
<td></td>
</tr>
<tr>
<td>9:00-9:15 am</td>
<td><strong>bb2121/KARMMA ph1 + 2 update</strong>&lt;br&gt;Noopur Raje, MD</td>
<td></td>
</tr>
<tr>
<td>9:15-9:30 am</td>
<td><strong>Juno JCAR125/EVOLVE update</strong>&lt;br&gt;Sham Mailankody, MBBS</td>
<td></td>
</tr>
<tr>
<td>9:30-9:45 am</td>
<td><strong>CT053/Carsgen</strong>&lt;br&gt;Hong Ma, MD</td>
<td></td>
</tr>
<tr>
<td>9:45-10:00 am</td>
<td><strong>Discussion</strong></td>
<td></td>
</tr>
<tr>
<td>10:00-10:30 am</td>
<td><strong>Break</strong></td>
<td></td>
</tr>
</tbody>
</table>

### SESSION 2: NEXT GENERATION BCMA CAR PRODUCTS IN THE CLINIC  
(Session Chairs: William Bensinger, MD and Kwee Yong, MBBS, PhD)

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:30-10:45 am</td>
<td><strong>bb21217</strong>&lt;br&gt;Jesus Berdeja, MD</td>
<td></td>
</tr>
<tr>
<td>10:45-11:00 am</td>
<td><strong>BCMA CAR + gamma secretase inhibition</strong>&lt;br&gt;Damian Green, MD</td>
<td></td>
</tr>
<tr>
<td>11:00-11:15 am</td>
<td><strong>Poseida transposon CAR</strong>&lt;br&gt;Caitlin Costello, MD</td>
<td></td>
</tr>
<tr>
<td>11:15-11:30 am</td>
<td><strong>Autolus APRIL based CAR</strong>&lt;br&gt;TBC</td>
<td></td>
</tr>
<tr>
<td>11:30-11:45 am</td>
<td><strong>NCI heavy chain based BCMA CAR</strong>&lt;br&gt;Lekha Mikkilineni, MD</td>
<td></td>
</tr>
<tr>
<td>11:45-12:00 pm</td>
<td><strong>Discussion</strong></td>
<td></td>
</tr>
<tr>
<td>12:00-1:00 pm</td>
<td><strong>Lunch</strong></td>
<td></td>
</tr>
<tr>
<td>1:00-1:30 pm</td>
<td><strong>Keynote Address: Approval of immune and cellular therapies for cancer: implications for myeloma</strong>&lt;br&gt;Nicole Gormley, MD</td>
<td></td>
</tr>
</tbody>
</table>
SESSION 3: CAR T CELL CORRELATIVE ANALYSES: UNDERSTANDING RESPONSE AND RESISTANCE
(Session Chairs: Madhav V. Dhodapkar, MBBS and Paola Neri, MD, PhD)

1:30-1:45 pm  **Correlates of response and resistance to CAR T cells: Lessons from CD19 experience**
                Joseph Fraietta, PhD

1:45-2:00 pm  **Single cell immune profiling after CAR T therapy in MM**
                TBC

2:00-2:15 pm  **bb2121 correlatives**
                Ethan G. Thompson, PhD

2:15-2:30 pm  **CARTITUDE-1 correlatives**
                Enrique Zudaire, PhD

2:30-2:45 pm  **Penn CART-BCMA correlatives**
                Adam Cohen, MD

2:45-3:00 pm  **Discussion**

3:00-3:30 pm  **Break**

SESSION 4: BEYOND BCMA: ALTERNATIVE CAR TARGETS
(Session Chairs: Amrita Krishnan, MD and TBC)

3:30-3:45 pm  **Rationale for targeting CD19**
                TBC

3:45-4:00 pm  **Combined BCMA and CD19 CAR T cells**
                Chengcheng Fu, MD, PhD

4:00-4:15 pm  **CD38 CAR T cells**
                Tuna Mutis, MD, PhD

4:15-4:30 pm  **GPRC5D CAR T cells**
                Eric Smith, MD, PhD

4:30-4:45 pm  **CRISPR/Cas9-edited NYESO-1 specific T cells**
                Edward Stadtmauer, MD

4:45-5:00 pm  **SLAMF7 CAR T cells**
                Michael Hudecek, MD

5:00-5:15 pm  **Discussion**

Saturday, May 8, 2021

SESSION 5: NOVEL CELL THERAPY APPROACHES FOR MM
(Session Chairs: Sagar Lonial, MD, FACP and TBC)

8:00-8:15 am  **SLAMF7 CAR T cells**
                Krina K. Patel, MD, MSc

8:15-8:30 am  **ALLO-715 and other off-the-shelf CARs for MM**
                TBC
SESSION 6: BISPECIFIC ANTIBODIES/T CELL ENGAGERS FOR MM
(Session Chairs: Suzanne Trudel, MD and Hearn Cho, MD)

10:00-10:15 am **AMG420**
Hermann Einsele, MD, FRCP

10:15-10:30 am **CC-93269**
Luciano J. Costa, MD, PhD

10:30-10:45 am **Belantamab mafodotin**
Sagar Lonial, MD, FACP

10:45-11:00 am **PF-06863135**
Alexander Lesokhin, MD

11:00-11:15 am **Mitigating CRS from bispecific antibodies**
Teemu Junttila, PhD

11:15-11:30 am Discussion

SESSION 7: TOXICITIES OF IMMUNE CELL THERAPY
(Session Chairs: Sundar Jagannath, MD and David S. Siegel, MD, PhD)

11:30-11:45 am **Pathophysiology and predictors of CRS**
Yi Lin, MD, PhD

11:45-12:00 pm **Management of CRS in 2020: Beyond toci/steroids?**
TBC

12:00-12:15 pm **Understanding and managing CAR T neurotoxicity**
Henrikas Vaitkevicius, MD

12:15-12:30 pm Discussion

12:30 pm Close and Lunch
THANK YOU TO OUR SPONSORS

This program is supported by a grant from Celgene Corporation.

International Myeloma Society
www.myelomasociety.org